siRNAs targeting CVB3 effectively inhibit viral replication and prevent cytotoxicity in vitro, highlighting a potential therapeutic strategy for enterovirus-induced diseases such as myocarditis.
May support siRNA development for CVB3 myocarditis; leaves open translation from HeLa cells to in vivo or clinical settings.
We examined the ability of small interfering RNAs (siRNAs) to disrupt infection by coxsackievirus B3 (CVB3). The incorporation of siRNAs dramatically decreased cell death in permissive HeLa cells in parallel with a reduction in viral replication. Three of four siRNAs had potent anti-CVB3 activity. The present study thus demonstrates that the antiviral effect is due to the downregulation of viral replication. In addition, an effective CVB3-specific siRNA had similar antiviral effects in other related enteroviruses possessing sequence homology in the targeted region. Because the CVB3-specific siRNA is effective against other enteroviruses, siRNAs have potential for a universal anti-enterovirus strategy.
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: